Company Filing History:
Years Active: 2015-2022
Title: Philippe Daull: Innovator in Ocular Treatment
Introduction
Philippe Daull, an accomplished inventor based in Soisy-sur-Seine, France, has significantly contributed to the field of ophthalmology with his innovative concepts and solutions. With a total of three patents to his name, Daull focuses on the treatment of ocular conditions, leveraging his expertise in pharmaceutical innovations.
Latest Patents
One of Philippe Daull's recent patents involves the use of polysaccharides for the treatment of ocular conditions. This invention highlights the beneficial properties of a polysaccharide derived from a bacterial strain in both the prevention and treatment of ocular diseases. Particularly, it emphasizes the ophthalmic usage of polysaccharides obtained from the CNCM I-5038 bacterial strain, targeting issues related to ophthalmic dryness and inflammation.
Another significant patent pertains to the use of prostaglandins F2alpha and their analogues for healing corneal and conjunctival lesions. This composition, designed for topical application on the ocular surface, is formulated to be free of harmful preservatives, thus ensuring safety and efficacy. The method developed by Daull includes administering a therapeutic amount of this innovative composition to patients experiencing surface ocular conditions.
Career Highlights
Philippe Daull is currently associated with Santen Sas, a company renowned for its commitment to developing innovative pharmaceutical solutions for eye care. His work at Santen Sas places him at the forefront of ocular research and development, contributing to advancements that enhance patient outcomes in eye health.
Collaborations
Throughout his career, Daull has collaborated with notable professionals in the field, including Christophe Baudouin and Jean-Sébastien Garrigue. These partnerships are instrumental in driving the research and application of his patented innovations, fostering a collaborative environment that enhances the development of effective ocular treatments.
Conclusion
Philippe Daull stands out as a prominent innovator in the realm of ocular health. With his latest patents focusing on polysaccharides and prostaglandins, he demonstrates a dedication to advancing treatments for ocular conditions. His role at Santen Sas and collaborations with talented colleagues further underscore his pivotal position in developing solutions that address complex eye care challenges.